MDR1 Drug Sensitivity Collie Breeds
By DVM Rounds·April 1, 2026·1 question
💊Pharmacology
🧭 Routing
The question is a direct inquiry about drug safety, contraindications, and dose adjustments related to the MDR1 (ABCB1) mutation, including a specific list of drugs. This falls squarely within the expertise of a veterinary pharmacologist.
💊Nadia VossPharmacology Specialist
Excellent. My MDR1/Breed Sensitivity Specialist has provided a solid foundation of the genetics and a comprehensive drug list. Let me synthesize this into a practical clinical framework.
The core issue with the MDR1 (ABCB1) mutation is the failure of a critical safety mechanism: the P-glycoprotein (P-gp) efflux pump. Think of P-gp as a bouncer at the door of the central nervous system and other sensitive tissues. It actively ejects certain drugs, preventing them from accumulating to toxic levels. In dogs with the mutation (especially homozygous M/M individuals), that bouncer is off duty. Drugs that are normally excluded walk right in and can't get out, leading to profound, often life-threatening, toxicity.
Here’s how I categorize these drugs in practice:
These drugs should be avoided entirely in M/M dogs, and used with extreme caution and significantly reduced doses in heterozygotes (N/M).
* Loperamide (Imodium®): This is the classic example. In a normal dog, it's an effective anti-diarrheal that doesn't cross the blood-brain barrier. In an MDR1-mutant dog, it causes profound sedation, respiratory depression, and can be fatal. It is absolutely contraindicated.
* Ivermectin (at high doses): The low doses used in monthly heartworm preventives (6-12 mcg/kg) are safe. However, the high doses used for treating demodectic mange or other parasites (300-600 mcg/kg) are contraindicated and will cause severe neurotoxicity (seizures, coma, death).
* Chemotherapy Agents (Vincristine, Doxorubicin): These are potent P-gp substrates. Giving a standard dose to an M/M dog results in dramatically increased exposure, leading to profound myelosuppression and gastrointestinal toxicity. For M/M dogs, the dose must be reduced by 50%; for N/M dogs, a 25-30% reduction is the standard starting point.
These drugs are P-gp substrates but can often be used safely if the dose is reduced and the patient is monitored closely.
* Acepromazine: Causes more profound and prolonged sedation in affected dogs. A dose reduction of 25-50% is prudent, especially in M/M individuals.
* Butorphanol: Similar to acepromazine, expect deeper and longer-lasting sedation. Start with a 25-50% lower dose.
* Cyclosporine: This immunosuppressant is a P-gp substrate. While not causing classic neurotoxicity, mutant dogs will have significantly higher drug bioavailability and blood concentrations. Therapeutic drug monitoring is essential to guide dosing and avoid systemic toxicity.
This is a critical category that often causes confusion. The key is the dose.
* Macrocyclic Lactone Heartworm Preventives:
* Ivermectin: Safe at the 6-12 mcg/kg dose in products like Heartgard®.
* Milbemycin Oxime: Safe at the labeled 0.5 mg/kg dose in products like Interceptor® or Sentinel®.
* Moxidectin: Safe at the labeled doses in products like Advantage Multi® (topical) and ProHeart® (injectable).
* Selamectin: Safe at the labeled dose in products like Revolution®.
The concentration of these drugs at the approved preventive doses is too low to cause CNS toxicity, even in M/M dogs. The danger arises only when these products are used off-label at much higher doses.
My clinical advice is straightforward: For any herding breed or mix, especially those listed by the specialist, genetic testing is the standard of care. It removes all guesswork. If a dog's status is unknown, you must assume it could be affected and choose non-P-gp substrate alternatives whenever possible. If you must use a substrate drug, dose for the worst-case scenario (M/M) and inform the owner about the risks and signs of toxicity to monitor for.
The core issue with the MDR1 (ABCB1) mutation is the failure of a critical safety mechanism: the P-glycoprotein (P-gp) efflux pump. Think of P-gp as a bouncer at the door of the central nervous system and other sensitive tissues. It actively ejects certain drugs, preventing them from accumulating to toxic levels. In dogs with the mutation (especially homozygous M/M individuals), that bouncer is off duty. Drugs that are normally excluded walk right in and can't get out, leading to profound, often life-threatening, toxicity.
Here’s how I categorize these drugs in practice:
1. High-Risk / Contraindicated
These drugs should be avoided entirely in M/M dogs, and used with extreme caution and significantly reduced doses in heterozygotes (N/M).
* Loperamide (Imodium®): This is the classic example. In a normal dog, it's an effective anti-diarrheal that doesn't cross the blood-brain barrier. In an MDR1-mutant dog, it causes profound sedation, respiratory depression, and can be fatal. It is absolutely contraindicated.
* Ivermectin (at high doses): The low doses used in monthly heartworm preventives (6-12 mcg/kg) are safe. However, the high doses used for treating demodectic mange or other parasites (300-600 mcg/kg) are contraindicated and will cause severe neurotoxicity (seizures, coma, death).
* Chemotherapy Agents (Vincristine, Doxorubicin): These are potent P-gp substrates. Giving a standard dose to an M/M dog results in dramatically increased exposure, leading to profound myelosuppression and gastrointestinal toxicity. For M/M dogs, the dose must be reduced by 50%; for N/M dogs, a 25-30% reduction is the standard starting point.
2. Use with Caution & Dose Adjustment
These drugs are P-gp substrates but can often be used safely if the dose is reduced and the patient is monitored closely.
* Acepromazine: Causes more profound and prolonged sedation in affected dogs. A dose reduction of 25-50% is prudent, especially in M/M individuals.
* Butorphanol: Similar to acepromazine, expect deeper and longer-lasting sedation. Start with a 25-50% lower dose.
* Cyclosporine: This immunosuppressant is a P-gp substrate. While not causing classic neurotoxicity, mutant dogs will have significantly higher drug bioavailability and blood concentrations. Therapeutic drug monitoring is essential to guide dosing and avoid systemic toxicity.
3. Generally Safe at Labeled Doses
This is a critical category that often causes confusion. The key is the dose.
* Macrocyclic Lactone Heartworm Preventives:
* Ivermectin: Safe at the 6-12 mcg/kg dose in products like Heartgard®.
* Milbemycin Oxime: Safe at the labeled 0.5 mg/kg dose in products like Interceptor® or Sentinel®.
* Moxidectin: Safe at the labeled doses in products like Advantage Multi® (topical) and ProHeart® (injectable).
* Selamectin: Safe at the labeled dose in products like Revolution®.
The concentration of these drugs at the approved preventive doses is too low to cause CNS toxicity, even in M/M dogs. The danger arises only when these products are used off-label at much higher doses.
My clinical advice is straightforward: For any herding breed or mix, especially those listed by the specialist, genetic testing is the standard of care. It removes all guesswork. If a dog's status is unknown, you must assume it could be affected and choose non-P-gp substrate alternatives whenever possible. If you must use a substrate drug, dose for the worst-case scenario (M/M) and inform the owner about the risks and signs of toxicity to monitor for.
MDR1/Breed Sensitivity Specialist
The MDR1 (Multidrug Resistance 1) gene, also known as ABCB1, encodes P-glycoprotein (P-gp), an efflux pump crucial for limiting drug absorption, facilitating drug elimination, and protecting the central nervous system (CNS) by actively transporting certain drugs out of the brain. A specific mutation (deletion) in this gene leads to a non-functional or deficient P-gp, resulting in increased systemic drug absorption, reduced drug elimination, and enhanced CNS penetration of P-gp substrate drugs. This significantly increases the risk of toxicity in affected dogs.
Affected Breeds:
The mutation is most prevalent in herding breeds and their crosses, including:
* Collie
* Australian Shepherd (Standard and Miniature)
* Shetland Sheepdog (Sheltie)
* Border Collie
* English Shepherd
* German Shepherd (some lines)
* Long-haired Whippet
* McNab
* Old English Sheepdog
* Silken Windhound
* Wäller
Testing Recommendations:
Genetic testing for the MDR1 mutation is strongly recommended for all at-risk breeds, especially before administering any P-gp substrate drugs. The Washington State University Veterinary Genetics Lab (WSU VGL) is a leading provider of this test.
* N/N (Clear): Two normal copies of the gene. Normal drug metabolism.
* N/M (Heterozygous): One normal and one mutant copy. May exhibit drug sensitivities, often requiring dose adjustments.
* M/M (Homozygous Affected): Two mutant copies. Highly sensitive to affected drugs, often requiring significant dose reductions or contraindication.
---
The following table provides safety categories and clinical notes for common P-gp substrate drugs in dogs with the MDR1 (ABCB1) mutation. These recommendations are general; individual patient assessment and close monitoring are always crucial.
| Drug | Safety Category | Clinical Note
Affected Breeds:
The mutation is most prevalent in herding breeds and their crosses, including:
* Collie
* Australian Shepherd (Standard and Miniature)
* Shetland Sheepdog (Sheltie)
* Border Collie
* English Shepherd
* German Shepherd (some lines)
* Long-haired Whippet
* McNab
* Old English Sheepdog
* Silken Windhound
* Wäller
Testing Recommendations:
Genetic testing for the MDR1 mutation is strongly recommended for all at-risk breeds, especially before administering any P-gp substrate drugs. The Washington State University Veterinary Genetics Lab (WSU VGL) is a leading provider of this test.
* N/N (Clear): Two normal copies of the gene. Normal drug metabolism.
* N/M (Heterozygous): One normal and one mutant copy. May exhibit drug sensitivities, often requiring dose adjustments.
* M/M (Homozygous Affected): Two mutant copies. Highly sensitive to affected drugs, often requiring significant dose reductions or contraindication.
---
Drug Safety Table for MDR1-Mutant Dogs
The following table provides safety categories and clinical notes for common P-gp substrate drugs in dogs with the MDR1 (ABCB1) mutation. These recommendations are general; individual patient assessment and close monitoring are always crucial.
| Drug | Safety Category | Clinical Note
Related Cases
Egg Binding Bird Emergency Treatment
🦜 Avian🚨 Emergency💊 Pharmacology
1 question
Gabapentin Veterinary Pain Protocol
💊 Pharmacology
1 question
Canine Glaucoma Emergency Treatment
👁️ Ophthalmology🚨 Emergency💊 Pharmacology
1 question
Canine Demodex Treatment Protocol
🔬 Dermatology💊 Pharmacology
1 question
Canine Immune Mediated Hemolytic Anemia
🩺 Internal Medicine🚨 Emergency💊 Pharmacology
1 question
Canine Idiopathic Epilepsy Management
🧠 Neurology💊 Pharmacology
1 question
Get Instant Specialist Consults
DVM Rounds connects you with 13 AI veterinary specialists and 45+ sub-agents. Ask any clinical question and get comprehensive, multi-specialist answers in seconds.
Start Free — No Credit Card